Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04299893 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ)

Study acronym: O3NPIQ
StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 2 entries Show 5 more changesShow less
    • Eligibility criteria expanded, about 22 words
    • Secondary endpoints: details revised at 9 of 18 entries
    • Collaborators: 5 to 6
    • Publications: details revised at 13 of 13 entries
    • Study description expanded, about 2 words
  2. Primary completion date: Dec 31, 2026 to Sep 30, 2027
    • Study completion date: Dec 31, 2026 to Dec 31, 2027
    v8
  3. Primary completion date: Oct 31, 2023 to Dec 31, 2026
    • Study completion date: Dec 31, 2023 to Dec 31, 2026
    v7
  4. Eligibility criteria shortened, about 8 words
    • Publications: 12 to 13
    • Study description expanded, about 1 word
    v6
  5. Re-verified, no change to tracked fieldsv5
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Primary completion date: Oct 31, 2022 to Oct 31, 2023
    • Study sites: 0 to 2
    • Study completion date: Jan 31, 2023 to Dec 31, 2023
    • Start date changed from estimate of Sep 2020 to Nov 30, 2020
  2. Start date: Mar 2020 to Sep 2020v3
  3. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main objective of this clinical trial is to evaluate the effectiveness and cost-effectiveness of adding ozone therapy to the clinical management of patients with pain secondary to chemotherapy-induced peripheral neuropathy
Trial Details
NCT Number NCT04299893
Lead Sponsor Bernardino Clavo, MD, PhD
Collaborators: Servicio Canario de Salud, Instituto de Salud Carlos III, Red de Investigación en Servicios de Salud en Enfermedades Crónicas, Fundación DISA, Spain, Fundación Española del Dolor (FED), Council of Gran Canaria
Conditions
(from sponsor)		 Chemotherapy-induced Peripheral Neuropathy, Pain, Neuropathic, Pain Syndrome
Related terms Neuralgia, Pain, Somatoform Disorders
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov